Morphotek Receives Ben Franklin Emerging Business Biotech Company Of The Year Award

Morphotek Inc. announced today that the Company has received the 2002 Biotech Company of the Year Award at the 8th Annual Ben Franklin Emerging Business Awards ceremonies in Philadelphia. The award, which is sponsored by S.R. One Limited, the venture capital fund of GlaxoSmithKline, honors an outstanding regional life sciences company that demonstrates novel technology, as well as the potential for significant impact on the treatment of disease. The selected company is recognized for its exceptional management team, prospects for achieving product commercialization in a reasonable period of time, and significant growth potential. Accepting the award for Morphotek were its three co-founders Dr. Nicholas C. Nicolaides, President and CEO, Dr. Philip M. Sass, Executive Vice-President and COO, and Dr. Luigi Grasso, Vice President of Research and Development.

Morphotek (www.morphotek.com) is a biotechnology company focused on the generation of proprietary organisms for product development using a patented platform technology that can enhance the natural process of genetic evolution within a targeted host. The technology has been successfully applied to microbes, plants, and mammals to yield genetically diverse offspring that are suitable for pharmaceutical and agricultural product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.
Back to 2002 News Archive